Search results for: Category

Baylor Dallas enrolling for clinical trial for patients with post-COVID-19 interstitial lung disease

Baylor University Medical Center at Dallas, part of Baylor Scott & White Health, is currently enrolling patients in ENDCOV-I: The Study of the Use of Nintedanib in Slowing Lung Disease in Patients with Fibrotic or Non-Fibrotic Interstitial Lung Disease (ILD) Related to COVID-19. Baylor Dallas is one of seven trial sites throughout the United States.

Read more

Baylor Scott & White researchers launch study to examine the impact of exercise on “long COVID” and COVID-19 recovery

The Centers for Disease Control and Prevention (CDC) has reported that an estimated 140 million Americans have been infected with the SARS-CoV-2 virus based on data collected from blood tests taken through January 2022. Many of these Americans are still feeling the after-effects of the virus known as post-acute sequelae of SARS-CoV-2 (PASC), or “long COVID.” The cases of PASC are becoming so common that lawmakers introduced a bill to fund research into the long-term effects of the disease and expand treatment resources for people experiencing them.

Read more